Australian based biosimilar manufacturer NeuClone has started phase 1 trials of its version of ustekinumab and has plans to launch other biosimilars for arthritic conditions. The Sydney-based manufacturer says it has commenced a dosing trial in Australian centres of a ustekinumab biosimilar candidate, NeuLara, in over 200 healthy volunteers. If approved by the TGA, the ...
Australian company has biosimilars in pipeline for arthritic conditions
By Michael Woodhead
30 Oct 2019